The oral hCG protocol for weight loss is© Dr. Daniel Belluscio.
 All rights reserved (please browse clicking here )

People deal too much with the negative, with what is wrong. Why not try and
see positive things, to just touch those things and make them bloom?

Thich Nhat Hanh Vietnamese Buddhist Monk, Teacher


Dr. Daniel Oscar Belluscio* M.D,
Dr. Leonor Ripamonte, M.D
Dr. Marcelo Wolansky Ph.D

* Correspondence and questions : 

Dr. Daniel Belluscio
Guido 1953
1119 Buenos Aires
Phone And Fax: 0054-011-4804 97 84


Female obese volunteers participating in a double blind study, and submitted to the administration of an oral presentation of hCG (Human Choriogonadotropin) plus a VLCD (Very Low Calorie Diet), decreased specific body circumferences and skinfold thickness from conspicuous body areas more efficiently than Placebo+VLCD -treated subjects.

Since a significant fat proportion from total body fat is subcutaneously located (50 to 65 percent, depending on sex and fat distribution), this hCG metabolic activity would result in a reduction of the total body fat mass, the main cause for obesity. We suggested that the combination of a VLCD and oral hCG could not only trigger clinically significant changes in subcutaneous fat stores but simultaneously decrease body weight and modelate body contour.

hCG oral administration proved to be a safe and effective procedure on obese treated volunteers. No side effects were observed during the study. There are no reports in the literature regarding this administration route to compare our findings.

Compared to placebo treated subjects, volunteers who were managed with an oral administration of hCG coped more efficiently with daily irritating situations, were in a better mood, and handled home conflicts without stepping up family discussions.

KEYWORDS: Gonadotropin(s), Chorionic; Obesity; Adipose tissue metabolism; fat ; overweight; beta-endorphin; lypolisis; lipogenesis.

Quite few substances have been so neglected and misunderstood regarding its potential therapeutic actions as hCG, the acronym for Human Chorionic Gonadotropin.

First discovered by Ascheim and Zondek as back as 1927 in the urine from pregnant women (2), thousands of articles were published regarding its action on gonads, but comparatively quite a few investigated its vast therapeutics potentialities, encompassing Kaposi sarcoma (33), asthma (63,65), psychoses (22,23), artheriopaties (14), thalassemia (7,19,56), osteopenia (56), glaucoma (53).

hCG is the glycoproteic hormone normally secreted by trophoblastic cells of the placenta during pregnancy (66). It consists of two dissimilar, separately, but most presumably coordinately translated chains, called the alpha and beta subunits. (12,26,47,27,18,30)

The three pituitary hormones LH (Luteinising Hormone), FSH (Follicle Stimulating Hormone) and TSH (Thyroid Stimulating Hormone) are closely related to hCG in that all fours are glycosilated and have a dimeric structure comprising the alpha and beta chains as well. (31,35,79)

The aminoacid sequence of alpha chain of all four human glycoproteic hormones is nearly identical. The aminoacid sequence of the Beta subunits differs and account for by the unique immunological and biological activities of each glycoproteic hormone (63). Beta hCG contains a carboxylic residue of 30 aminoacids characteristic to hCG (11,52)

Its denomination (Human Chorionic Gonadotropin) dates back from the early days, when it was found hCG rendered mature the infantile sex glands in experimentation animals (Gonadotropin) and it was secreted by the placentary chorion (Chorionic) (2,91).

However, recent data suggest both terms can be misleading: normal human tissues from non-pregnant subjects (88,74,48,86,87), trophoblastic and non-trophoblastic tumors (33,6,90), bacteria (49), and plants (46,69) express hCG or a hCG-like substance.

The first report on hCG and obesity was published back as 1954 in The Lancet, by a British born physician, graduated in Germany, Dr. A.T.W. Simeons (70). Dr. Simeons was born in London in 1900 and graduated in medicine at the University of Heidelberg. After further studies in Germany and Switzerland he moved to Dresden where he was appointed to a large surgical Hospital.

He got very involved in tropical diseases and joined the school of Tropical Medicine in Hamburg. He later moved to work in Africa for a while. Later he went to India (1931) he became fascinated with the country and its health problems and stayed there for 18 years. In 1949 he moved to Rome where he continued his work on psychosomatic disorders at the Salvatore Mundii Hospital.

After its publication, hCG was advocated for several years as an useful approach to obesity. The pendulum of its popularity swinged back and forth until a serial of studies (1,3,8,17,36) but three (3,25,80) concluded hCG was of no use to manage the disease

According to basic pharmacological postulates, the administration route may influence the biological activity of a drug. All previous studies were performed with a hCG preparation administered by injections. One of the authors of this study (DB) theorized that an increase in dose and a shifting in hCG administration to a sublingual-enteral route may modify the pharmacological activity of hCG.

The purpose of this study was to assess the utility of an oral presentation hCG for the management of obesity.

  • Materials and methods

The study design was of the double-blind type: neither treating physician nor patient knowing who was receiving hCG, or an inert substance (placebo). Female patients for the study were selected, since the clinic where the study was performed specializes in the diagnosis and treatment of gynecologic disorders.

Details of the protocol were explained to eighty-three volunteers, who were solicited through a written announcement. Before being entered the study they signed an informed consent in front of a neutral witness.

We required selected volunteers to meet the following criteria: being at least 25 % BMI (Body Mass Index) overweight, and in general healthy condition. If taking medication for obesity, such as anorectics or amphetamines, they should discontinue the medication at least one month prior the initiation of the study.

Drugs to control their clinical diseases (hypertension, hypothyroidism, etc.) were allowed. No patients under steroid, diuretics or hormones were entered the study. During the study, volunteers were also asked about starting the use of medical prescribed drugs or pharmaceutical preparations during the trial period.

No teenagers and patients over 75 y.o were admitted to the study. No patients with severe and/or uncontrolled clinical diseases (cancer, IDDM, heart attacks, infarcts sequelae) were accepted. After applying the inclusion/exclusion criteria, we counted on 70 subjects to divide in treatment groups.

These women were randomly assigned to groups Placebo (P, N=26) or hCG (N=44) by a simple randomized sampling method. This latter group was in turn splitted in two subgroups: G1 (N=36) and G2 (N=8), according to the hCG dose administered (see below).

Patients were Caucasic, ages ranging from 23 to 73 y.o (group P: 41 ± 13; group G1: 42 ± 12; group G2: 41 ± 14), a range of heights of 1,62 cm. to 1,81 cm., and overweight ranging from 25 to 49,9 on BMI Tables.

Since there were no published reports on the oral use of hCG, group G2 was administered twice the dose of G1, to assess if hCG concentration may affect obtained results.

The pharmacist prepared two types of vials: one containing saline solution (Na Cl 0,9% w/v), and the other containing a diluted and buffered solution of standardized hCG .

Vials were randomly labeled, each number corresponding with a patient. The pharmacist kept the codes in a sealed envelope. They were opened after completing the protocol.

To obtain a complete copy of the procedures, please email your request to oralhcgmethod@hcgobesity.org  .
You must be a Licensed Healthcare Professional to get a copy.

The same Very-Low-Calorie-Diet (VLCD), specific and detailed, was prescribed to all groups.

Breakfast: tea or coffee in any quantity without sugar. Only one tablespoonful of milk allowed in 24 hr. Saccharin or other sweeteners could be used.

Lunch: 100 grams. of veal, beef, chicken breast, fresh white fish, lobster, crab or shrimp. All visible fat was carefully removed before cooking, and the meat weighed raw. Salmon, tuna fish, herring, dried or pickled fish was not allowed.

The chicken breast was removed raw from the bird. One type of vegetable could be only chosen from the following: spinach, chard, chicory, beet-greens, green salad, tomatoes, celery, fennel, onions, red radishes, cucumbers, asparagus, and cabbage. One breadstick (grissini) or one Melba toast was allowed, and an apple or an orange, or a handful of strawberries or one-half grapefruit.

For dinner: The same four choices as lunch.

The juice of only one lemon daily was allowed for all purposes. Salt, pepper, vinegar, mustard power, garlic, sweet basil, parsley, thyme, marjoram, etc., could be used for seasoning, but no oil, butter or dressing. Tea, coffee, plain water, mineral water were the only drinks allowed, but they could be taken in any quantity and always.

Volunteers assisted twice weekly at the clinic to be controlled and weighed. The following evaluations were completed once a week:

I. Height and Weight,
performed on a medical scale. Volunteers were weighed using normal underwear

II. Body circumferences. Using a flexible, non elastic metric tape, the following anatomic areas were assessed:

  • Wrist (WRT), at the level of flexion fold (wrist-forearm);

  • Breast (BRE), submammary fold;

  • Waist (WAT): at the hypogastric region level;

  • Abdominal (ABD), at the navel level;

  • Hips (HIP): pubic line;

  • Thighs (THI): 8 cm. below pubic line;

  • Suprapatelar (ROT), at the patella upper border;

  • Ankle (ANK), at the flexion fold (peroneal protuberance).

III. Skinfold thickness. Using a Lange Skinfold Caliper (Cambridge Scientific Industries, Cambridge, Maryland), the following folds were examined:

  • Tricipital (TRI), arm midline, posterior region and tricipital muscle zone;

  • Anterior Axilar line (AXA), at the fold created when pinching the skin region at the level of the pectoralis muscle extending to the arm;

  • Subscapular (SCA (I)): inferior scapular spine;

  • Thoracic (TOR): at the fold created when pinching the region located immediately below the ribs, at the level of an imaginary line extending from anterior axilar line;

  • Suprailiac (ILI), at the fold created 4 cm above the anterior superior iliac spine;

  • Supraumbilical (UMB(u)), 3 cm above navel;

  • Infraumbilical (UMB(l)), 3 cm below navel;

  • Thighs (THI), internal aspect of thighs, eight cm below the pubic area;

  • Patellar area (ROT), at the fold created when pinching the region located 6 cm medial to the internal patellar border.

IV. Bioelectrical impedance. Using Tetrapolar Bioelectrical Impedance (TBI) with a body fat analyzer Maltron, model BF-905 (Maltron International Ltd., Rayleigh, Essex).

Volunteers voided previous to the evaluation, placed on supine position , and allowed to rest half an hour before determination. Self-adhering electrodes were placed on extremities. Every determination was performed with a separate set of electrodes, discarded after single use.

The following TBI determinations were assessed:

1. Fat weight (FW),
2. Lean weight (LW),
3. Water weight (WW),
4. Calories (CAL).

V. b-hCG determinations: all subjects enrolled in the trial were studied for plasmatic b-hCG levels by an ELISA test (64) on 0-15-30 study days.

VI. Mood questionnaire: from the first study week on, patients were given weekly self-administered questionnaires to be completed at home. It consisted of twenty-four questions related to their mood changes in the course of the study, plus four questions related to adverse drug effects. They returned the data at the time of the subsequent visit to the clinic.

Variables were splitted as follows for a better data processing and statistical results presentation:

· Category I, BW plus four bioelectrical impedance records (FW, LW, WW and CAL),

· Category II, eight anthropometrical measurements (corporal circumferences WRT, BRE, WAT, ABD, HIP, THI, ROT and ANK).

· Category III, nine skinfold assessments (TRI, AXA, SCA (I), TOR, ILI, UMB(u), UMB(l), THI, ROT) (see long names and definitions for the studied variables at the beginning of this section).

Each set was analyzed with a two-way multivariate analysis of variance (MANOVA), comparing the obtained Wilks-lambda' F with the corresponding critical value.

TREATMENT (VLCD diet plus group-specific pharmacological intervention) was considered the between-subject factor with three levels (P, G1, G2), and WEEK of clinicometric control served as an additional within-subject factor with six levels: weeks 0 to 5.

To estimate how the differences between treatment' groups depended on the trial time elapsed since week zero (comparison of pattern trend changes in function of treatment time) we obtained the MANOVA result for the effect of the INTERACTION (also displayed in the text as TREATMENT x WEEK).

Moreover, to prevent any possible influence of acute effects specifically associated to any VLCD program in the adaptation phase (first 5-7 days), we additionally evaluated with separate MANOVA analyses the differences between groups and within subjects in the course of the last four treatment's weeks.

After obtaining a statistically significant multivariate test for a particular main effect or interaction, we further examined the univariate F tests for each dependent variable. When parameters from these tests displayed significant modifications, data were further analyzed to ascertain which group (P, G1 or G2) was the responsible for the previous p values obtained.

We also compared data basal values from each group against those obtained in subsequent weeks (e.g., records of week 0 against week 1, thereafter against week 2, and so on). These pairwise comparisons were statistically assessed applying a post hoc Scheffé F tests.

Questionnaire responses were converted into percentages and submitted to a chi-square (2c) test to compare between-groups and within-groups (pairing off final vs. initial data) statistic results.

To attenuate the natural source of within-subject variation, inherent to all assessments of subjective symptoms, we averaged data results from identical questionnaires completed weekly during the initial first two study weeks. Thus, we obtained a more precise "initial questionnaire" (avoiding the potential "adaptation effect" common to any VLCD regime in the first treatment week).

To obtain the final mood behavior results over the last two treatment weeks, they were averaged using the same schema as detailed before. Criteria for significance was p<0.05. Statistica 4.2 (from StatSoft, Inc.) for Windows software was used in all processing.

(Figures 1, 2, 3 ,4 and 5)

All volunteers were submitted to the same VLCD schedule lasting five weeks. The objective of this study was to gather data on the potential synergism between hCG administration and a VLCD plan.

At the end of the study we counted a total of 4.3 % missing data due to the absence of subjects in control days (no one absent in more than two opportunities) because personal situations not associated with the experimental conditions.

No statistic differences were obtained among Placebo and hCG groups regarding missing data.

1. Regarding weight loss, similar results (with/without hCG administration) were obtained. Bioelectrical impedance exhibited discrete modifications in tested groups

As expected, for all types of clinicometric assessments, significant results were obtained through MANOVA analysis on factor WEEK. Figures 1 and 2 (bioelectrical impedance and anthropometrical data, respectively) show that the time-dependent changes were uniformly present in all tested groups.

We therefore estimated that the decreasing observed patterns were the consequence of VLCD acting on overweight patients. However, regarding skinfold thickness findings (Figures 3 and 4), we detected in P group a noticeable tendency to attenuation of the within-subject variation during the last (third to fifth) study weeks.

The data suggested us that this latter period might be the focus of our interest (see detailed analysis below).

Figure 1 shows data patterns resulting in all groups from three representative variables (BW, FW and LW) of the variable category I. The MANOVA analysis revealed nearly significant differences for the INTERACTION (TREATMENT x WEEK) [F(50,58) =1.35 , p=0.13] without statistical significance on analysis of TREATMENT as main effect [F(10,98)=1.22, p=0.29].

When all groups were submitted to multivariate and univariate analyses taking exclusively data from weeks 2-5, we observed no significant difference result for the INTERACTION among group P and hCG-treated groups. This finding could be related to differences in mean basal body weights and treatment-dependent responses to the acute effects of VLCD during former weeks.

When post hoc Scheffé test was applied to compare the result from each weekly record (weeks 1-5) to it's corresponding basal value (week zero), we found similar patterns for all groups concerning analysis of BW and TBI records (compare P vs. hCG-treated groups in every panel of Figure 1).

However, regarding the analysis of FW and BW data, we detected significant differences for the effect of the INTERACTION (p<0.005 and p<0.05, respectively). Comparing FW patterns from groups P and G1: F (5,230)=4.55, p<0.001. For the comparison P vs. G2, (BW and FW data), we obtained: F(5,140)=4.20 and 2.97, respectively (p<0.01 for both cases).

2. hCG+diet  decreased more significantly waist and abdominal circumferences than diet alone

Figure 2 shows the results for three (category II) body circumference assessments (WAT, ABD and HIP). MANOVA analysis showed significant differences for factor TREATMENT as main effect [F (16,92)=1.92, p<0.04], which we do not consider relevant due to the presence of higher basal records in group G2 when compared to the rest of the studied groups.

As a whole, the effect of the INTERACTION did not reveal statistical significance.

Nevertheless, significant differences were obtained after further analysis for the effect of the INTERACTION on variable WAT [F (10,265)=2.44, p<0.01, see panel A].

Data assessments from other circumferences did not show statistical differences for this effect among groups [as representative examples, see ABD (p=0.35) and HIP records in panels B and C, respectively].

When the records of weeks 0-1 were subtracted from MANOVA analysis, almost all p values were slightly affected. WAT and ABD measurements demonstrated to be still more affected by the INTERACTION: for WAT, p<0.003; for ABD, p<0.08.

The INTERACTION significance increased when P controls were compared to subjects from group G2: comparing P vs. G2, and considering data from weeks 0-5, we obtained: F (5,140)=2.87 (p<0.02) for WAT, and F(5,140)=1.80, (p=0.12) for ABD. But when we analyzed data from weeks 2-5, we found the following: for WAT, F (3,84)=3.43 (p<0.02), for ABD, F (3,84)=2.73 (p<0.05).

3. Weak effects of hCG on a series of skinfold thickness reduction patterns

Figures 3 and 4 show results from subcutaneous fat evaluations, as assessed by skinfold thickness, on nine selected skinfolds.

Figure 3 presents three representative folds [TRI, SCA (l), ILI (u)] out of five (those previous mentioned plus AXA and TOR) that demonstrated to be slightly affected by the pharmacological treatment.Analyzing skinfold data from weeks 0 to 5, the main effect TREATMENT showed statistical significance (F(10,98)=2.39, p<0.02).

However, prevailing higher basal records in group G2 might account for this statistical significance. After studying the effect of the INTERACTION on skinfold results, statistics were as follow: TRI (see panel A), p<0.08; AXA, p=0.98; SCA (l) (see panel B), p<0.005; ILI (see panel C), p=0.23; TOR, p=0.35.

Performing pairwise comparisons among control P and hCG-treated groups, we observed that the higher significances obtained for SCA (l) and TRI skinfolds derived mainly from the comparison among P and G2: for TRI, F (5,140)=2.55, p<0.04, for skinfold SCA (l), F (5,140)=6.02, p<0.0001.

MANOVA analysis run on weeks 2-5 data resulted in a significance increase for TREATMENT as main effect [F (10,98)=2.55, p<0.009]. In addition, the INTERACTION was enhanced on data from SCA (l) assessment (p<0.00005): by comparing data from groups P and G2 during weeks 2 to 5: for TRI, F (3,84)=2.08 (p<0.04), for SCA (l), F (3,84)=9.31.

4. Higher response rates in a different skinfold series by treatment with hCG plus a VLCD

In Figure 4 we display skinfold thickness results obtained from another series of four examined skinfolds [UMB (u), UMB (l), THI, ROT (u)]. MANOVA analysis resulted in a nearly significant INTERACTION [F (40,68)=1.55, p<0.06] without statistical significance for TREATMENT as main effect [F(8,100)=1.43, p=0.20].

When the specific effect of the INTERACTION was evaluated for each skinfold, highly significant differences were found. By computing F (10,265) values, we obtained the following results: UMB (u) (see panel A), p<10-3; UMB (l) (see panel B), p<10-5; ROT (see panel C), p<0.05; THI (see panel D), p<10-6.

When we restricted the data analysis from weeks 2 to 5, we found nearly significant results for factor TREATMENT as main effect [F (8,100)=1.75, p<0.1] and for the effect of the INTERACTION [F (24,84)=1.55, p<0.06].

The INTERACTION was further studied pairing P group against each hCG-treated group in separate multivariate analyses. By comparing P vs. G1, we found: for UMB( l) , p<0.04, and for ROT , p<0.03 (UMB(u) and THI achieved nearly significant p values). Again, the strength of the INTERACTION [TREATMENT x WEEK] was higher when group G2 was selected for the comparison.

From the obtained data, it becomes clear that skinfolds determinations in G2 subjects showed a differential response to VLCD schedule with respect to that of P controls (for INTERACTION, in these points of skinfold assessment, p<0.0005).

5. Selective response of some skinfolds to hCG was dependent on dose

The experimental design of this investigation was not intended to determine the dose-response curve for hCG acting on diet-induced effects.

However, the effects of hCG on some of these skinfolds seemed to be dependent on dose, since it was found significant differences for the effect of the INTERACTION after the comparison between G1 vs. G2 groups for UMB (u) (p<0.001) and UMB (l) (p<0.005), and a nearly significant p value for THI (p=0.11).

Figure 4 also displays the percentages of skinfold thickness reduction from the beginning to the end of the clinical trial. We found skinfolds decreases for group G1 ranging from over 22% (for UMB (u), see panel A) up to over 115% (for THI, see panel D) over respective decreases in P group.

These differences were still higher when G2-subjects were compared to P controls: by computing the ratio between decrease percentages, G2 had over twice (for UMB (u), see panel A) to over four-fold (for THI, see panel D) the skinfold records drops observed in group P (see each actual percentage, group by group, in Fig. 4).

Most of the differences among hCG-treated subjects and P controls regarding skinfold reduction rates were enhanced when data corresponding to week five was compared to records of week two instead week zero (data not shown).

6. Improvement in mood-related parameters by  hCG

In Figure 5 we display the responses to four representative questions asking about the occurrence frequency for specific mood-related events, according to a multiple choice designed questionnaire completed every treatment week by all the subjects enrolled in the trial.

Panels A to D display the initial and final questionnaire results, expressed as percentages for each optional response (covering a four-option frequency scale from never to frequent).

Using this procedure, we expected to find in tested volunteers skewness towards either sense concerning their behaviors and feelings in response to a diet and a pharmacological intervention.

For all these questions, and compared to control subjects, hCG-treated volunteers (G1+G2) showed a trend to improvement of interpersonal contacts and mood control when confronting upsetting or conflicting situations.

Pairing off final (f) vs. initial (i) distribution of percentages for optional responses, we particularly found statistical significance in two of these questions in group G (after 2c test: 2c3=16.3, p<0.002, and 2c3=7.82, p<0.05; see right sectors of panel A and B, respectively).

P group-subjects did not present temporal differences (see panel A), or were adversely affected in their mood during the trial 2c3=14.4, p<0.002 (compare in panel B corresponding initial and final values for group P and G).

Furthermore, group P exhibited in other two questions certain skewness to the impairment of its mood (see left half of panels C and D, p<10-5 ); for group G we obtained the 2c3 values 1.51 and 3.98, respectively (p>0.3), showing the absence of temporal mood changes.
For all other mood-related questions, no statistical significant difference among groups was found (data not shown).

We also included some questions intended to evaluate the potential occurrence of treatment-dependent clinical anomalies regarding hormonal, physiological or metabolic disorders. We found no significant difference after final vs. initial records' comparison (data not shown).

7. No detectable b-hCG plasmatic levels in all tested groups

On treatment days 0, 15 and 30 we have tested all volunteers, screening for the presence of plasmatic b-hCG. Concentrations were undetectable in all cases (data not shown).

Concerning hCG and its utility for the management of obesity, this study introduces two new aspects, and adds new data for a third:

I) This is the first report assessing variables not included in previous reports (38,51,68,89);

II) We report a new administration route for hCG management of obesity, the oral approach, which has never been reported before;

III) We have detected mood changes in hCG treated patients, regarding a better confrontation of daily emotionally conflicting situations.

These assertions will be separately discussed:

I) Skinfold thickness (SKF) and Tetrapolar Bioelectric Impedance (TBI) records.

Both approaches have been extensively discussed in the literature. It was shown that the correlation between the values obtained with the two methods to be linear and highly significant for both sexes (42,81,27).

There is general agreement that skinfolds calipers are particularly useful in the clinical setting (56,82,16,76,10,65, 9,15,75), particularly in view of the fact that measurement of subcutaneous body fat at different body sites is becoming increasingly important for the characterization of risk of certain disease states (55).

When comparing skinfolds assessments to body circumference estimates, despite some data suggest that the latter approach appears to be more sensitive in the determination of subcutaneous body fat (53), this procedure is in our opinion subjected to clinical variables (bloating syndrome after a meal, premenstrual water retention, etc.) that may affect negatively on the final estimates results.

Also, when comparing SKF to body contour assessments, some data suggest that the pattern of fat thickness body distribution measured over several specific sites by one method of measurement is unlikely to be duplicated by of the other method on the same individual (40,41).

Adipose tissue patterns show great variability, showing the importance of using skinfold caliper readings from a variety of different anatomic sites including upper limbs, lower limbs and trunk (30,65).

According to the above conclusions from several authors (72,13,60, 25,73,62), we would like to suggest that former studies on hCG and obesity lacked of sufficient data to estimate accurately modifications of adipose tissue distribution in tested volunteers. Consequently we designed the study to assess as many as possible variables.

As far as our study concerns, we subjected each volunteer enrolled in the trial to four bioelectrical impedance, eight anthropometrical plus nine SKF evaluations. Performing this multiple site determinations, our results show that specific SKF are highly responsive to hCG pharmacological intervention (upper and lower umbilical).

The greater response was obtained in those regions where the corresponding circumference assessments resulted in nearly significant or significant decreases through the trial period (see waist and abdomen records in Fig. 2 and the above detailed description of statistical results for the effect of the interaction).

II) Oral hCG is an valuable alternative administration route

No data appear on the scientific literature regarding an oral administration of hCG in humans. But results from this study suggests hCG may be used by the sublingual-enteral route. Despite plasmatic ß-hCG remained undetectable both in Placebo and hCG groups throughout the study, an oral administration of hCG proved to possess therapeutic activity.

Since commercial preparations of hCG contains ß-endorphin (see below), it may be tempting to hypothesize that this pentapeptide might account for the pharmacological activity observed on mood stability during the Protocol.

III) Volunteers treated with hCG coped better with daily irritating situations.

As can be seen on Figure 5, hCG-treated groups handled better their irritability, their mood at home, and were less prone to episodes of extreme nervousness capable of provoking violent discussions . Several reports proposed hCG might be used for the treatment of psychoses or neurosis (29,61,24). Our study appears to corroborate these proposals.

To conclude, this study poses several still unanswered questions:

1. hCG plasmatic levels. We have tested all volunteers, screening for the b-hCG in plasma. Concentrations were undetectable in all cases.

Therefore, which hCG fraction is responsible for the pharmacological activity observed in our study? hCG molecular size (alpha chain -14,500 KD; beta chain -22,200 KD) makes highly improbable that the entire molecule has been absorbed. Our hypothesis is that only a fraction of the entire hCG molecule is absorbed through this administration route .

2. hCG and lipid metabolism. We do not know precisely how hCG acts on adipose tissue metabolism. However, some reports (32,84,85,83 ) suggest hCG possesses a metabolic activity on adipose tissue (i.e. decrease lipogenesis). These actions are not directly exerted on adipocytes, since fat cell membranes have no receptors for hCG (32).

3. hCG and mood. A stable mood and lack of attrition characterized the hCG-treated group.

It is well known that VLCD's are associated with mood changes, particularly attrition (78) during the dieting period. In one study, disinhibition and hunger were significantly related to anxiety and depression while restraint was not (44). Another study concluded that elevated levels of anxiety persist in female patients throughout a VLCD course of treatment (45).

Also many patients complain about fatigue during a VLCD (4).

Conversely, our data suggest that hCG-treated volunteers rather improved their attitude towards their environment, in the sense of an enhanced well-being, less irritability and lack of fatigue. Since commercial preparations of hCG contains b-endorphin (39) and this neuropeptide has been demonstrated to affect the function of limbic-emotional circuits (21,58,5,28), we hypothesized that the b-endorphin fraction present in commercial preparations of hCG might account for the activity observed regarding mood control.

Additional studies remain to be performed to test the validity of this hypothesis.

  • Conclusions

1. Female obese volunteers participating in a double blind study, and submitted to the administration of an oral presentation of hCG plus a VLCD, decreased specific body circumferences and skinfold thickness from conspicuous body areas more efficiently than Placebo+VLCD -treated subjects.

Since a significant fat proportion from total body fat is subcutaneously located (50 to 65 percent, depending on sex and fat distribution), this hCG metabolic activity would result in a reduction of the total body fat mass, the main cause for obesity. We suggested that the combination of a VLCD and oral hCG could not only trigger clinically significant changes in subcutaneous fat stores but simultaneously decrease body weight and modelate body contour.

2. hCG oral administration proved to be a safe and effective procedure on obese treated volunteers. No side effects were observed during the study. There are no reports in the literature regarding this administration route to compare our findings.

3. Compared to placebo treated subjects, volunteers managed with an oral administration of hCG coped more efficiently with daily irritating situations, were in a better mood, and handled home conflicts without stepping up family discussions.
This study appears to contradict former conclusions on the issue of hCG and obesity. We attribute those differences to a different approach, including variables not assessed in former publications.

The hCG and obesity  Research Clinic
Director: Dr. Daniel Belluscio
Phone and Fax+54-11-4804 97 84
Phone+54-11-4807 18 83

Proceedings of the First International Workshop on hCG and obesity
(click here)


Copyright © Dr. Daniel Belluscio 1992-2009. All rights reserved

Supervised the translation and spelling of this website